Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

While they share similarities, there are differences, particularly between the drugs semaglutide and tirzepatide.

Research has found that people with OSA are more likely to develop type 2 diabetes, and more than half of people with type 2 diabetes have sleep apnea. Plus, sleep apnea deprives the body of ...

A recent study revealed that individuals with an inherited susceptibility to obstructive sleep apnea (OSA) are at increased risk for ... Key Findings • The main MR analysis with IVW (fixed effects) ...

Green Bay Packers running back Josh Jacobs, a 27-year-old from Tulsa, Oklahoma, overcame a turbulent childhood to rise through the ranks of professional football. His journey from homelessness to NFL ...